New Biomarkers to Predict the Evolution of in Situ Breast Cancers

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Sep 23

PMID 25243117

Citations 9

Authors

S Bravaccini

M M Tumedei

E Scarpi

W Zoli

C Rengucci

L Serra

A Curcio

F Buggi

S Folli

A Rocca

R Maltoni

M Puccetti

D Amadori

R Silvestrini

Affiliations

Soon will be listed here.

Abstract

Background: Genomic studies have shown that gene expression profiles are similar in in situ (CIS) and invasive breast cancers, suggesting that several biofunctional modifications of the transformation process occur before or during the development of CIS lesion.

Methods: We investigated 3 biomarkers in 44 patients with CIS: TG2 (transglutaminase 2), HJURP (Holliday junction recognition protein), and HIF-1α (hypoxia inducible factor-1 alpha).

Results: TG2 was more highly expressed than the other two markers and significantly more so in stromal than in tumor cells. HIF-1α evaluation showed a higher expression in both tumor and stromal cells in patients with relapsed G3 tumors, indicating a potential role of this marker in CIS evolution. A greater than sevenfold higher risk of relapse (P = 0.050) was observed in patients highly expressing HJURP in stroma and a tenfold higher recurrence risk (P = 0.026) was seen in those with a higher stromal HIF-1α expression. An important increase in risk accuracy (AUC 0.80) was obtained when HIF-1α and HJURP were evaluated together.

Conclusions: Despite the limited number of relapsed patients, we formulated some hypotheses on the factors responsible for malignant evolution and recurrence which are now being tested in a large case series with a longer follow-up.

Citing Articles

Transglutaminase 2 in breast cancer metastasis and drug resistance.

Li M, Wang X, Hong J, Mao J, Chen J, Chen X Front Cell Dev Biol. 2024; 12:1485258.

PMID: 39544364 PMC: 11560871. DOI: 10.3389/fcell.2024.1485258.

The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia.

Pergaris A, Genaris I, Stergiou I, Klijanienko J, Papadakos S, Theocharis S Cancers (Basel). 2023; 15(21).

PMID: 37958340 PMC: 10650673. DOI: 10.3390/cancers15215165.

Advances in holliday junction recognition protein (HJURP): Structure, molecular functions, and roles in cancer.

Li L, Yuan Q, Chu Y, Jiang H, Zhao J, Su Q Front Cell Dev Biol. 2023; 11:1106638.

PMID: 37025176 PMC: 10070699. DOI: 10.3389/fcell.2023.1106638.

A three layered histone epigenetics in breast cancer metastasis.

Nandy D, Rajam S, Dutta D Cell Biosci. 2020; 10:52.

PMID: 32257110 PMC: 7106732. DOI: 10.1186/s13578-020-00415-1.

Transcriptomic response of breast cancer cells to anacardic acid.

Schultz D, Krishna A, Vittitow S, Alizadeh-Rad N, Muluhngwi P, Rouchka E Sci Rep. 2018; 8(1):8063.

PMID: 29795261 PMC: 5966448. DOI: 10.1038/s41598-018-26429-x.

References

Mangala L, Arun B, Sahin A, Mehta K . Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer. 2005; 4:33. PMC: 1224867. DOI: 10.1186/1476-4598-4-33. View

Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate K . Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000; 19(48):5435-43. DOI: 10.1038/sj.onc.1203938. View

van der Groep P, van Diest P, Smolders Y, Ausems M, van der Luijt R, Menko F . HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS One. 2013; 8(2):e56055. PMC: 3568038. DOI: 10.1371/journal.pone.0056055. View

Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G . SLUG silencing increases radiosensitivity of melanoma cells in vitro. Cell Oncol (Dordr). 2012; 36(2):131-9. DOI: 10.1007/s13402-012-0120-6. View

Hayes D, Isaacs C, Stearns V . Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2002; 6(4):375-92. DOI: 10.1023/a:1014778713034. View

Korkeila E, Jaakkola P, Syrjanen K, Sundstrom J, Pyrhonen S . Preoperative radiotherapy downregulates the nuclear expression of hypoxia-inducible factor-1alpha in rectal cancer. Scand J Gastroenterol. 2009; 45(3):340-8. DOI: 10.3109/00365520903483635. View

Coates P, Dewar J, Thompson A . At last, a predictive and prognostic marker for radiotherapy?. Breast Cancer Res. 2010; 12(3):106. PMC: 2917011. DOI: 10.1186/bcr2567. View

Holland R, Peterse J, Millis R, Eusebi V, Faverly D, van de Vijver M . Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994; 11(3):167-80. View

Cleator S, Ashworth A . Molecular profiling of breast cancer: clinical implications. Br J Cancer. 2004; 90(6):1120-4. PMC: 2409657. DOI: 10.1038/sj.bjc.6601667. View

10.

Gundemir S, Colak G, Feola J, Blouin R, Johnson G . Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Biochim Biophys Acta. 2012; 1833(1):1-10. PMC: 3518673. DOI: 10.1016/j.bbamcr.2012.10.011. View

11.

Bijker N, Peterse J, Duchateau L, Julien J, Fentiman I, Duval C . Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001; 19(8):2263-71. DOI: 10.1200/JCO.2001.19.8.2263. View

12.

Hu Z, Huang G, Sadanandam A, Gu S, Lenburg M, Pai M . The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res. 2010; 12(2):R18. PMC: 2879562. DOI: 10.1186/bcr2487. View

13.

Agnihotri N, Kumar S, Mehta K . Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res. 2013; 15(1):202. PMC: 3745644. DOI: 10.1186/bcr3371. View

14.

Skinner K, Silverstein M . The management of ductal carcinoma in situ of the breast. Endocr Relat Cancer. 2001; 8(1):33-45. DOI: 10.1677/erc.0.0080033. View

15.

Bravaccini S, Granato A, Medri L, Foca F, Falcini F, Zoli W . Biofunctional characteristics of in situ and invasive breast carcinoma. Cell Oncol (Dordr). 2013; 36(4):303-10. DOI: 10.1007/s13402-013-0135-7. View

16.

Leonard G, Swain S . Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004; 96(12):906-20. DOI: 10.1093/jnci/djh164. View